Clinical Trial

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Study acronym: TRONTIER 2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Protocol Amendment History 2 changes
notable Trial sites expanded: 146 -> 150 locations 2026-05-12
notable Trial sites expanded: 135 -> 146 locations 2026-04-14
Trial Details
NCT Number NCT07170150
Lead Sponsor Hoffmann-La Roche
Conditions Alzheimers Disease
Enrollment 800 participants
Start Date 2025-11-12
Primary Completion 2028-06-07 (estimated)
Study Completion 2028-06-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-06